Partnership for Protecting Coverage letter to the U.S. Department of Health and Human Services outlining patient priorities for the 2025 Notice of Benefits and Payment Parameters.
Site Search
CF Foundation letter to the Ohio governor and state legislature thanking them for funding the Children and Youth with Special Health Needs program and Ohio Medicaid in the 2024-2025 budget.
CF Foundation letter to the Senate Finance Committee in support of the Modernization and Ensuring PBM Accountability Act which would enhance accountability and address the opaque influence of pharmacy benefit managers.
The CF Foundation writes to Michigan’s House Committee on Insurance and Financial Services to provide comments on SB 483: The Prescription Drug Cost and Affordability Review Act, which would create a prescription drug affordability board in the state.
In a letter sent to Colorado’s Prescription Drug Affordable Board, the Cystic Fibrosis Foundation provides feedback on the board’s review of Trikafta®, including concerns around the board’s proposed methodology, and provides a compilation of published data on Trikafta’s effects on clinical outcomes and other health care utilization.
The Cystic Fibrosis Foundation, European Cystic Fibrosis Society, and Cystic Fibrosis Europe provided comments to the European Medicines Agency on draft guidance on establishing efficacy of a new treatment based on single-arm trials.
CF Foundation letter thanking Michigan’s governor for providing adequate funding for the Children’s Special Health Care Services program and Medicaid in the state’s 2024 budget, both of which play an important role in ensuring consistent access to care for Michiganders living with CF.
Ad hoc patient coalition provides comments to the U.S. Department of Health and Human Services supporting Washington’s proposal to extend continuous eligibility to the Children’s Health Insurance Program to children under six years of age in the state.
CF Foundation letter to Michigan’s Committee on Insurance and Financial Services supporting HB 4719, which would require insurers to apply third party assistance to out-of-pocket maximums and other patient cost-sharing requirements.
CF Foundation letter thanking the California Department of Health Care Services for including certain CF medications on the state's list of medications eligible for extended duration prior authorization under Medi-Cal Rx and requesting the inclusion of additional medications to that list.